Available EXPANDED_ACCESS NCT04008524

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Conditions Relapsed and Refractory Hematological Malignancies

Interventions CAR-T cells

Updated 9 times since 2019 Last updated: Aug 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04008524, this observational or N/A phase trial focuses on Relapsed and Refractory Hematological Malignancies and remains ongoing. Sponsored by Institute of Hematology & Blood Diseases Hospital, China, it has been updated 9 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Available
Apr 2025 — Sep 2025 [monthly]

Available
Sep 2024 — Apr 2025 [monthly]

Available
Jul 2024 — Sep 2024 [monthly]

Available
Oct 2023 — Jul 2024 [monthly]

Available

▶ Show 4 earlier versions

Sep 2022 — Oct 2023 [monthly]

Available
Mar 2021 — Sep 2022 [monthly]

Available
Jan 2021 — Mar 2021 [monthly]

Available
Aug 2019 — Jan 2021 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Hematology & Blood Diseases Hospital, China
Juventas Cell Therapy Ltd.

Data source: Institute of Hematology & Blood Diseases Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China